ESC 2020

Novartis' inclisiran cuts bad cholesterol levels by at least 30%

Despite pandemic-related setbacks in its clinical program this year, Novartis has continued to stack up favorable data for cholesterol med inclisiran.

Conor Hale Aug 30, 2020 10:39am

MyoKardia's mavacamten boosts heart function in phase 3 study

Aug 29, 2020 1:10pm

Researchers aim to build saliva-based heart attack test

Aug 26, 2020 3:00pm